TY - JOUR
T1 - Upconversion Nanoparticle Powered Microneedle Patches for Transdermal Delivery of siRNA
AU - Wang, Min
AU - Han, Yiyuan
AU - Yu, Xiaojun
AU - Liang, Liangliang
AU - Chang, Hao
AU - Yeo, David C.
AU - Wiraja, Christian
AU - Wee, Mei Ling
AU - Liu, Linbo
AU - Liu, Xiaogang
AU - Xu, Chenjie
PY - 2020/1/22
Y1 - 2020/1/22
N2 - Microneedles (MNs) permit the delivery of nucleic acids like small interfering RNA (siRNA) through the stratum corneum and subsequently into the skin tissue. However, skin penetration is only the first step in successful implementation of siRNA therapy. These delivered siRNAs need to be resistant to enzymatic degradation, enter target cells, and escape the endosome–lysosome degradation axis. To address this challenge, this article introduces a nanoparticle-embedding MN system that contains a dissolvable hyaluronic acid (HA) matrix and mesoporous silica-coated upconversion nanoparticles (UCNPs@mSiO2). The mesoporous silica (mSiO2) shell is used to load and protect siRNA while the upconversion nanoparticle (UCNP) core allows the tracking of MN skin penetration and NP diffusion through upconversion luminescence imaging or optical coherence tomography (OCT) imaging. Once inserted into the skin, the HA matrix dissolves and UCNPs@mSiO2 diffuse in the skin tissue before entering the cells for delivering the loaded genes. As a proof of concept, this system is used to deliver molecular beacons (MBs) and siRNA targeting transforming growth factor-beta type I receptor (TGF-βRI) that is potentially used for abnormal scar treatment.
AB - Microneedles (MNs) permit the delivery of nucleic acids like small interfering RNA (siRNA) through the stratum corneum and subsequently into the skin tissue. However, skin penetration is only the first step in successful implementation of siRNA therapy. These delivered siRNAs need to be resistant to enzymatic degradation, enter target cells, and escape the endosome–lysosome degradation axis. To address this challenge, this article introduces a nanoparticle-embedding MN system that contains a dissolvable hyaluronic acid (HA) matrix and mesoporous silica-coated upconversion nanoparticles (UCNPs@mSiO2). The mesoporous silica (mSiO2) shell is used to load and protect siRNA while the upconversion nanoparticle (UCNP) core allows the tracking of MN skin penetration and NP diffusion through upconversion luminescence imaging or optical coherence tomography (OCT) imaging. Once inserted into the skin, the HA matrix dissolves and UCNPs@mSiO2 diffuse in the skin tissue before entering the cells for delivering the loaded genes. As a proof of concept, this system is used to deliver molecular beacons (MBs) and siRNA targeting transforming growth factor-beta type I receptor (TGF-βRI) that is potentially used for abnormal scar treatment.
KW - microneedles
KW - scar treatment
KW - small interfering RNA
KW - transdermal drug delivery
KW - upconversion nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85076132065&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85076132065&origin=recordpage
U2 - 10.1002/adhm.201900635
DO - 10.1002/adhm.201900635
M3 - RGC 21 - Publication in refereed journal
C2 - 31788987
SN - 2192-2640
VL - 9
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 2
M1 - 1900635
ER -